CN1882705A - 遗传多态性用于预测药物诱导肝脏毒性的用途 - Google Patents

遗传多态性用于预测药物诱导肝脏毒性的用途 Download PDF

Info

Publication number
CN1882705A
CN1882705A CNA2004800344189A CN200480034418A CN1882705A CN 1882705 A CN1882705 A CN 1882705A CN A2004800344189 A CNA2004800344189 A CN A2004800344189A CN 200480034418 A CN200480034418 A CN 200480034418A CN 1882705 A CN1882705 A CN 1882705A
Authority
CN
China
Prior art keywords
locus
hepatotoxicity
genotype
gene
il1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800344189A
Other languages
English (en)
Chinese (zh)
Inventor
K·麦卡洛
C·D·沃尔夫冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1882705A publication Critical patent/CN1882705A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800344189A 2003-10-06 2004-10-05 遗传多态性用于预测药物诱导肝脏毒性的用途 Pending CN1882705A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50897203P 2003-10-06 2003-10-06
US60/508,972 2003-10-06

Publications (1)

Publication Number Publication Date
CN1882705A true CN1882705A (zh) 2006-12-20

Family

ID=34520003

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800344189A Pending CN1882705A (zh) 2003-10-06 2004-10-05 遗传多态性用于预测药物诱导肝脏毒性的用途

Country Status (14)

Country Link
US (1) US20070248955A1 (enExample)
EP (1) EP1673472B1 (enExample)
JP (1) JP4979382B2 (enExample)
CN (1) CN1882705A (enExample)
AT (1) ATE498021T1 (enExample)
AU (1) AU2004283234B2 (enExample)
BR (1) BRPI0415299A (enExample)
CA (1) CA2540760C (enExample)
DE (1) DE602004031352D1 (enExample)
ES (1) ES2361018T3 (enExample)
MX (1) MXPA06003827A (enExample)
PL (1) PL1673472T3 (enExample)
PT (1) PT1673472E (enExample)
WO (1) WO2005040415A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116239665A (zh) * 2023-03-10 2023-06-09 山东大学 Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10262107B1 (en) * 2013-03-15 2019-04-16 Bao Tran Pharmacogenetic drug interaction management system
CN108949947B (zh) * 2017-05-25 2022-06-28 上海市预防医学研究院 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
WO2002030920A1 (en) * 2000-10-12 2002-04-18 Takeda Chemical Industries, Ltd. Benzimidazole compounds, process for producing the same and use thereof
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116239665A (zh) * 2023-03-10 2023-06-09 山东大学 Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用

Also Published As

Publication number Publication date
AU2004283234B2 (en) 2007-08-30
US20070248955A1 (en) 2007-10-25
JP2007512231A (ja) 2007-05-17
AU2004283234A1 (en) 2005-05-06
ATE498021T1 (de) 2011-02-15
WO2005040415A1 (en) 2005-05-06
CA2540760C (en) 2013-01-08
ES2361018T3 (es) 2011-06-13
PT1673472E (pt) 2011-05-12
PL1673472T3 (pl) 2011-07-29
EP1673472A1 (en) 2006-06-28
MXPA06003827A (es) 2006-06-14
JP4979382B2 (ja) 2012-07-18
DE602004031352D1 (de) 2011-03-24
CA2540760A1 (en) 2005-05-06
BRPI0415299A (pt) 2006-12-26
EP1673472B1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
CN1177059C (zh) 与il-1基因座多态性相关之炎性疾病的预测方法
CN1293203C (zh) 大规模鉴定疾病基因型的方法和6型脊髓小脑共济失调的诊断试验
CN1890384A (zh) 与炎性疾病的治疗功效相关的遗传多态性的用途
CN1604968A (zh) 基于tcf1基因多态性治疗糖尿病和相关病症的方法
CN1806051A (zh) 通过(例如)t细胞受体v/d/j基因中的重复鉴定克隆性细胞
CN1612941A (zh) 基于cntf基因的多态性治疗精神病和精神分裂症的方法
CN1754000A (zh) 预测治疗中自杀行为的方法
CN1882705A (zh) 遗传多态性用于预测药物诱导肝脏毒性的用途
CN1635142A (zh) 用于预测偏执型精神分裂症易感性的试剂盒及所用引物
CN1671841A (zh) 基因多态性分型方法
CN101056990A (zh) 表皮生长因子受体基因启动子的多态性
CN1761760A (zh) hsgk1基因中新的多态性在诊断高血压中的用途和sgk基因家族在诊断和治疗长Q/T综合征中的用途
CN1833023A (zh) 药物性粒细胞过少症发病几率判定法
CN1685062A (zh) 预测免疫抑制治疗期间胆固醇升高的方法
CN1942480A (zh) 与高脂血症、血脂障碍和糖代谢缺陷相关的SNPs的鉴别
CN1882604A (zh) 肥胖症的遗传标记
CN1891822A (zh) 具有特定单核苷酸多态性的th基因及其检测方法和用途
CN1515686A (zh) 用于预测糖尿病易感性的试剂盒及所用引物
CN1515685A (zh) 用于预测糖尿病易感性的试剂盒及所用引物
CN1625603A (zh) 前速激肽原基因中的遗传多态性
CN1548556A (zh) 用于预测2型糖尿病易感性的试剂盒及引物
CN1928083A (zh) 人类异源物质代谢酶基因的单核苷酸多态性及其在诊断和治疗大肠癌方面之应用
CN101033487A (zh) 检测与原发性高血压相关的KLK1基因rs5517多态的方法
CN1771337A (zh) 包含单核苷酸多态性且与结肠癌有关的多核苷酸、包括该多核苷酸的微阵列和诊断试剂盒以及用该多核苷酸诊断结肠癌的方法
CN1871349A (zh) 预测紫杉醇疗法副作用的方法及试剂盒

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication